Most Read Articles
12 Nov 2019
Use of the feminizing hormone therapy medroxyprogesterone acetate (MPA) results in minimal side effects, unchanged oestradiol levels and a decline in testosterone in a cohort of transwomen, a study has found.
29 Sep 2019
The duration and degree of overweight in adulthood appear to have lasting influence on breast and colorectal cancer survival, a study has found.
22 Jul 2019
The risk of diabetes mellitus is higher among postmenopausal women who develop primary breast cancer, reports a new study.

Vitamin D, oestrogen protect against metabolic syndrome after menopause

17 Jul 2019

Deficiencies in vitamin D and oestrogen contribute to additive increases in the risk of metabolic syndrome in postmenopausal women, a recent study has found.

The cross-sectional study included 616 postmenopausal women aged 49-86 years. None of them were taking oestrogen and vitamin D/calcium supplements. Researchers measured serum oestradiol (E2) and 25(OH)D for each participant in relation to the risk of metabolic syndrome, which was defined according to the 2006 International Diabetes Federation standard.

Results showed a positive correlation between 25(OH)D and E2. Higher 25(OH)D concentration was associated with a favourable lipid profile, blood pressure and glucose level. On the other hand, higher E2 concentration was associated with low levels of cholesterol, triglycerides and blood pressure.

Women with vitamin D deficiency were twice as likely as those with sufficient vitamin D levels to have metabolic syndrome (odds ratio [OR], 2.19, 95 percent CI, 1.19–4.01; p-trend=0.009). This association remained significant despite controlling for E2 levels.

On further analysis stratifying by vitamin D status, low E2 concentration augmented the risk of metabolic syndrome in women with vitamin D deficiency (lowest vs highest tertile of E2: OR, 3.49, 1.45–8.05).

The present data suggest that vitamin D and E2 deficiencies exert a potential synergistic effect on the risk of metabolic syndrome in postmenopausal women, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
12 Nov 2019
Use of the feminizing hormone therapy medroxyprogesterone acetate (MPA) results in minimal side effects, unchanged oestradiol levels and a decline in testosterone in a cohort of transwomen, a study has found.
29 Sep 2019
The duration and degree of overweight in adulthood appear to have lasting influence on breast and colorectal cancer survival, a study has found.
22 Jul 2019
The risk of diabetes mellitus is higher among postmenopausal women who develop primary breast cancer, reports a new study.